摘要
目的:探讨芪苈强心胶囊联合沙库巴曲缬沙坦钠片治疗慢性心力衰竭的可行性。方法:选取2020年12月-2021年2月在佳木斯市中心医院住院的慢性心力衰竭患者122例为研究对象,利用随机数字表法将其分为对照组(n=61)和试验组(n=61)。给予对照组沙库巴曲缬沙坦钠片进行治疗,试验组在对照组基础上联合芪苈强心胶囊治疗。比较两组治疗前、治疗6周后心脏收缩和舒张功能改善情况、血清各项指标及并发症发生情况。结果:治疗前,两组心脏收缩和舒张功能、血清指标比较,差异均无统计学意义(P>0.05);治疗6周后,两组左室射血分数(left ventricular ejection fraction,LVEF)、心排血量(cardiac output,CO)、每搏输出量(stroke volume,SV)均升高,试验组均高于对照组,差异均有统计学意义(P<0.05);两组可溶性人基质裂解素2(soluble suppression of tumorigenicity 2,sST_(2))、N末端脑钠肽前体(N-terminal pro-brain nitric peptide,NT-proBNP)水平均降低,试验组均低于对照组,差异均有统计学意义(P<0.05)。试验组并发症发生率低于对照组,差异有统计学意义(P<0.05)。结论:芪苈强心胶囊联合沙库巴曲缬沙坦钠片应用在慢性心力衰竭患者中,可改善心脏收缩和舒张功能,降低病灶炎症反应,减少并发症发生。
Objective:To explore the feasibility of Qiliqiangxin Capsules combined with Shakubatqu Valsartan Sodium Tablets in the treatment of chronic heart failure.Method:A total of 122 patients with chronic heart failure hospitalized in Jiamusi Central Hospital from December 2020 to February 2021 were selected as the research objects,they were divided into control group (n=61) and experimental group (n=61) by random number table method.The control group was treated with Shakubatqu Valsartan Sodium Tablets,while the experimental group was treated with Qiliqiangxin Capsules on the basis of the control group.The improvement of cardiac systolic and diastolic function,serum indexes before and 6 weeks after treatment and complications were compared between the two groups.Result:Before treatment,there were no significant differences in the improvement of cardiac systolic and diastolic function and serum indexes between the two groups (P>0.05);after 6 weeks of treatment,the left ventricular ejection fraction (LVEF),cardiac output (CO) and stroke volume (SV) of the two groups all increased,those of the experimental group were significantly higher than those of the control group,the differences were statistically significant (P<0.05);the levels of soluble suppression of tumorigenicity 2 (sST_(2)) and N-terminal pro-brain natriuretic peptide (NT-proBNP) decreased in both groups,those of the experimental group were lower than those of the control group,with statistical significance (P<0.05).The incidence of complications in the experimental group was lower than that in the control group,the difference was statistically significant (P<0.05).Conclusion:Qiliqiangxin Capsules combined with Shakubatqu Valsartan Sodium Tablets can improve cardiac systolic and diastolic function,reduce focal inflammatory reaction and reduce complications in patients with chronic heart failure.
作者
李欣
LI Xin(Jiamusi Central Hospital,Heilongjiang Province,Jiamusi 154002,China)
出处
《中国医学创新》
CAS
2022年第15期70-73,共4页
Medical Innovation of China
基金
佳木斯大学基础研究类(自然类)项目(JMSUJCMS2016-048)。
关键词
慢性心力衰竭
芪苈强心胶囊
沙库巴曲缬沙坦钠片
Chronic heart failure
Qiliqiangxin Capsules
Shakubatqu Valsartan Sodium Tablets
